From HMG through purified urinary FSH preparations to recombinant FSH: A substitution study

Human Reproduction

Volumn 17, Issue 4, 2002, Pages 857-865

  Zwart Van Rijkom, J E F ^a,b   Broekmans, F J ^c   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Drug policy; FSH; HMG; IVF; Technology assessment

Indexed keywords

GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOTECHNOLOGY; CLINICAL TRIAL; CONSUMER; COST BENEFIT ANALYSIS; DRUG CONTAMINATION; DRUG COST; DRUG DIFFUSION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SYNTHESIS; FERTILIZATION IN VITRO; GOVERNMENT; HORMONE URINE LEVEL; HUMAN; INFERTILITY; MEDICAL PRACTICE; META ANALYSIS; NETHERLANDS; POSTMENOPAUSE; PROTEIN CONTENT; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0036111442     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.4.857     Document Type: Review

References (50)

1. The challenge of meta-analysis and the need to register clinical trials
2. Follicle-stimulating hormone or human menopausal gonadotrophin for ovarian stimulation in in-vitro fertilization cycles: A meta-analysis
3. Shortage of medicines
4. Hormone treatment for IVF
5. Availability of gonadotropins
6. The challenge of meta-analysis and the need to register clinical trials
7. What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins
8. Reduced awareness of hypoglycemia after changing from porcine to human insulin in IDDM
9. Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus
10. What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone
11. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques
12. Do indications for transfusion of plasma still exist?
13. Uneasy alliance-clinical investigators and the pharmaceutical industry
14. Letter to all Dutch gynaecologists
15. Letter to all Dutch gynaecologists
16. Availability of gonadotropins
17. Availability of gonadotropins
18. Medicines for ovulation induction
19. The challenge of meta-analysis and the need to register clinical trials
20. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
21. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: A meta-analysis
22. Letter to all Dutch gynaecologists
23. Risk of severe hypoglycaemia in insulin treated diabetic patients transferred to human insulin: A case control study
24. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists
25. Hypoglycaemia and human insulin
26. Insulin treatment for the early 80s: Facts and questions about old and new insulins and their usage
27. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome
28. The clinical benefits of recombinant gonadotrophins
29. Interactions between physicians and the pharmaceutical industry: What does the literature say?
30. Pharmaco-economic aspects of in-vitro fertilization in Italy
31. Product choice and haemophilia treatment in the Netherlands
32. What are the clinical benefits of recombinant gonadotrophins? Is Puregon a 'good' or 'super' drug?
33. Recombinant follicle-stimulating hormone (FSH); How much longer 'grandmothers' for mothers?
34. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
35. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies
36. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins
37. What are the clinical benefits of recombinant gonadotrophins?: The development of recombinant FSH Puregon R: A scientific business
38. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy
39. Ovarian stimulation during assisted reproduction treatment: A comparison of recombinant and highly purified urinary human FSH. On behalf of the Feronia and Apis study group
40. Letter to all Dutch pharmacists
41. Letter to all Dutch gynaecologists
42. Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome
43. Assessment of biotechnology drugs: What are the issues?
44. Availability of gonadotropins
45. Physicians and the pharmaceutical industry: Is a gift ever just a gift?
46. Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands - The Dutch results from the EUROMET project